Back to homepage


Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis

Authors: George J Wan PhD, Ishveen Chopra PhD, John Niewoehner PharmD, Samuel F Hunter MD, PhD

The objective of this study was to estimate the cost per response of repository corticotropin injection compared with plasmapheresis or intravenous immunoglobulin from the United States commercial payer perspective.


Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority metaanalytical approach

Authors: Philippe Lehert Dr Ir PhD, Cassandra Szoeke MD, GAICD, PhD, FRACP, AMA(M), MBBS

This research assesses the non-inferiority of pitolisant, a new compound for the relief of excessive daytime sleepiness and cataplexy in narcolepsy, compared with modafinil.


Neurological features of COVID-19 and their treatment: a review

Authors: Daniele Orsucci MD, Elena Caldarazzo Ienco MD, Gianpaolo Nocita MD, Alessandro Napolitano MD, Marco Vista MD

This review aims to summarize early findings on
the neurological features of COVID-19 and their treatment


Tics and Tourette’s syndrome

Authors: Shivam Om Mittal MD

Tics and Tourette’s syndrome are common hyperkinetic movement disorders seen mostly in the pediatric age group. This review emphasizes the diagnosis and distinguishing of Tourette’s from other movement disorders.


Efficacy and safety of a GABAergic drug (Gamalate® B6): effects on behavior and cognition in young adults with borderline-to-mild intellectual developmental disabilities and ADHD

Authors: Ramón Novell MD, Susanna Esteba-Castillo PhD, Emili Rodriguez PhD

Gamalate B6 was evaluated in patients
with borderline intellectual functioning or mild intellectual
development disability and found to be effective and well tolerated for ADHD and challenging behavior.